We study the use of anaerobic non-pathogenic recombinant clostridia as a highly tumor-specific cancer treatment
Bacterial Gene Therapy
John T. Heap*, Jan Theys*, Muhammad Ehsaan, Aleksandra M Kubiak, Ludwig Dubois, Kim Paesmans, Lieve Van Mellaert, Richard Knox, Sarah A. Kuehne, Phillipe Lambin, and Nigel P. Minton (2014). Spores of Clostridium engineered for clinical efficacy and safety cause regression and cure of tumors in vivo. OncoTarget, advanced online publication (*equal contribution).
J. Theys, O. Pennington, L. Dubois, W. Landuyt, J. Anné, P. Burke, G. Anlezark, P. Dϋrre, B.G. Wouters, N.P. Minton and P. Lambin (2006). Repeated systemic treatment cycles of Clostridium-directed enzyme prodrug therapy results in sustained anti-tumour effects in vivo. Brit J Cancer, 95, 1212-1219.
Asferd Mengesha, Ludwig Dubois, Roland K. Chiu, Kim Paesmans, Bradly G. Wouters, Philippe Lambin and Jan Theys. (2007) The Tumor Microenvironment as a Target for Bacterial Delivery: What do We (not) Know? Frontiers in BioSciences, 12: 3880-91.
KWF Anaerobic Clostridium
Grant # UM 2015-8025
Project coordinator: Prof. Philippe Lambin/Dr. Jan Theys
Sum awarded: 2.085 k€
Funded by: KWF
Use of non-pathogenic engineered clostridia as delivery vector for toxic gene products to the tumor (ZonMW)
Grant # 4340009
Project coordinator: Dr. Jan Theys
Sum awarded: 800 k€
Funded by: ZonMW
Please follow this link to see all the grants received by MaastroLab